Loading…

Variability in Bleeding Phenotype in Type 3 VWD Families

Type 3 von Willebrand Disease (VWD) is a rare and severe form of VWD characterized by complete absence of von Willebrand factor (VWF). Patients with type 3 VWD typically present with moderate to severe mucocutaneous bleeding as well as muscle hematomas and hemarthroses. While inheritance has classic...

Full description

Saved in:
Bibliographic Details
Published in:Blood 2018-11, Vol.132 (Supplement 1), p.2466-2466
Main Authors: Christopherson, Pamela A, Flood, Veronica H, Haberichter, Sandra L, Gill, Joan Cox, Montgomery, Robert R, Investigators, Zimmerman Program
Format: Article
Language:English
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Type 3 von Willebrand Disease (VWD) is a rare and severe form of VWD characterized by complete absence of von Willebrand factor (VWF). Patients with type 3 VWD typically present with moderate to severe mucocutaneous bleeding as well as muscle hematomas and hemarthroses. While inheritance has classically been considered autosomal recessive, there is increasing evidence for co-dominant inheritance, with heterozygous carriers affected with low VWF levels. We sought to explore the bleeding phenotype in type 3 index cases (IC) and family members (FM) enrolled in the Zimmerman Program study using the ISTH bleeding assessment tool (ISTH-BAT), and to correlate baseline bleeding score (ISTH BS) and sequence variant (SV) location as well as analyze prospective bleeding diatheses over time using an interim bleeding score (iBAT). Analysis included type 3 VWD index cases (IC), type 3 FM, type 1 affected family members (AFM) and healthy controls (HC). Clinical laboratory phenotyping was performed at BloodCenter of Wisconsin and included FVIII, VWF:Ag, VWF:RCo, VWFpp, VWF:CB3 and multimer analysis. Genotyping involved full-length VWF sequencing, array comparative genomic hybridization to detect deletions and Fabric Genomics Opal software to determine pathological variants. Bleeding symptoms were quantified using the ISTH-BAT bleeding score where baseline scores (ISTH BS) included entire history at time of enrollment and interim bleeding scores (iBAT) that represented bleeding occurring since the initial ISTH BS was obtained. Type 3 obligate carriers (OC) were defined as either having offspring with type 3 VWD or being an offspring of an individual with type 3 VWD. Type 1 AFM cohort included subjects with type 1/low VWF who were related to a type 1 IC. The type 3 families consisted of 45 unrelated type 3 IC, 56 OC with type 1/low VWF (Type 3 OC), 23 normal unaffected OC, and 8 unaffected family members (UFM). Clinical phenotyping and study entry ISTH BS are detailed in Table 1. Type 3 OC with type 1/low VWF (n=56) had mean VWF:Ag and VWF:RCo lab values which were not different from type 1/low VWF AFM (n=483) however both FVIII (68 vs 56, p
ISSN:0006-4971
1528-0020
DOI:10.1182/blood-2018-99-112961